Home › Research › Treatments
Neurochemical Ameliorating of the Hippocampus in Dyslipidemic Alzheimer Patients Following Silymarin; a Double-Blind Placebo-Controlled Randomized Clinical Trial
Rustamzadeh A, Sadigh N, Shabani R, Ahadi R, Vahabi Z, Shabani A, Mohebi N, Khamseh F et al.. Medical journal of the Islamic Republic of Iran, 2023-11-18
Topic: Brain proteins, microglia and lab models
Plain-language summary
Background Amyloid-beta (Aβ) production is a normal physiological process, and an imbalance in Aβ production/excretion rate is the basis of the plaque load increase in AD. LRP1 is involved in both central clearance of Aβ from the CNS and transport of Aβ toward peripheral organs. In this study, the effect of silymarin combination compared to rosuvastatin and placebo on neuro-metabolites and serum levels of LRP1 and Aβ1-42 proteins and oxidative stress enzymes and lipid and cognitive tests of Iranian AD patients. Methods In this double-blind placebo-controlled study, thirty-six mild AD patients were divided into groups (n=12) of silymarin 140mg, placebo, and rosuvastatin 10mg. Medications were administered 3 times a day for 6 months. Clinical tests, lipid profile (TG, HDL, TC, and LDL), Aβ1-42, and LRP1 markers were measured at the beginning and end of the intervention. Magnetic resonance spectroscopy (MRS) was used to measure metabolites. Using SPSS software a one-way ANOVA test was used to compare the means of the quantitative variables and Pearson and Spearman's correlations to measure the correlation. GraphPad Prism software was used for drawing graphs. P Results The levels of LRP1 and Aβ1-42 in the silymarin group were significantly increased compared to the other groups ( P P P = 0.003 and r = 0.595, P = 0.004, respectively). NAA/Cr of the right and left hippocampus was inversely related to TG (r = -0.511, P = 0.0033, and r = -0.532, P = 0.0021, respectively). NAA/Cr and NAA/mI of bilateral hippocampi directly correlated with HDL ( P P = 0.000 and r = -0.638, P = 0.000, respectively). Conclusion Donepezil and silymarin improved lipid profile associated with increased NAA/Cr, and decreased mI/Cr, in AD patients. Biomarker NAA/mI can be clinically significant in examining AD pathology. Measurement of the lipid factors and neurometabolites can be a suitable method for monitoring this disease.
What this study adds
Evidence grade: Low
The record lists 12 participants. In this small trial of 36 patients with mild Alzheimer's disease, silymarin increased levels of LRP1 and Aβ1-42 and improved lipid profile compared with other groups. The study was small and short, and it did not report clear cognitive benefits, so it does not show that silymarin treats Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rustamzadeh, A., Sadigh, N., Shabani, R., Ahadi, R., Vahabi, Z., Shabani, A., et al. (2023). Neurochemical Ameliorating of the Hippocampus in Dyslipidemic Alzheimer Patients Following Silymarin; a Double-Blind Placebo-Controlled Randomized Clinical Trial. Medical journal of the Islamic Republic of Iran. https://doi.org/10.47176/mjiri.37.123
Vancouver
Rustamzadeh A, Sadigh N, Shabani R, Ahadi R, Vahabi Z, Shabani A, et al. Neurochemical Ameliorating of the Hippocampus in Dyslipidemic Alzheimer Patients Following Silymarin; a Double-Blind Placebo-Controlled Randomized Clinical Trial. Medical journal of the Islamic Republic of Iran. 2023. doi:10.47176/mjiri.37.123. PMID: 38318412.
BibTeX
@article{rustamzadeh2023-38318412,
author = {Rustamzadeh, A. and Sadigh, N. and Shabani, R. and Ahadi, R. and Vahabi, Z. and Shabani, A. and Mohebi, N. and Khamseh, F. and others},
title = {{Neurochemical Ameliorating of the Hippocampus in Dyslipidemic Alzheimer Patients Following Silymarin; a Double-Blind Placebo-Controlled Randomized Clinical Trial}},
journal = {Medical journal of the Islamic Republic of Iran},
year = {2023},
doi = {10.47176/mjiri.37.123},
pmid = {38318412},
url = {https://doi.org/10.47176/mjiri.37.123}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- In this study, the effect of silymarin combination compared to rosuvastatin and placebo on neuro-metabolites and serum levels of LRP1 and Aβ1-42 proteins and oxidative stress enzymes and lipid and cognitive tests of Iranian AD patients.
- P Results The levels of LRP1 and Aβ1-42 in the silymarin group were significantly increased compared to the other groups ( P P P = 0.003 and r = 0.595, P = 0.004, respectively).
- Conclusion Donepezil and silymarin improved lipid profile associated with increased NAA/Cr, and decreased mI/Cr, in AD patients.
- Biomarker NAA/mI can be clinically significant in examining AD pathology.
Why it matters
In this small trial of 36 patients with mild Alzheimer's disease, silymarin increased levels of LRP1 and Aβ1-42 and improved lipid profile compared with other groups. The study was small and short, and it did not report clear cognitive benefits, so it does not show that silymarin treats Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants12
- Evidence strengthLow
How this study scored 39/100
Published in a peer-reviewed journal. Scored zero for study design and effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Medical journal of the Islamic Republic of Iran) |
| Journal's citation record | 0 / 4 | Medical Journal of the Islamic Republic of Iran: journal h-index 38 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 12 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 1 / 7 | Cited 4 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.8 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 1 / 6 | Cited 0.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Fatemeh Moradi: h-index 21 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Tehran University of Medical Sciences: institution h-index 810 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38318412) |
| Free to read | 2 / 2 | Free to read |
| Total | 39 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.47176/mjiri.37.123
- PubMed: 38318412
- Original source →
- Free full text: Medical Journal of the Islamic Republic of Iran →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.